Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX The FDA may be about to change everything for peptide research. Secretary RFK Jr. announced plans to move 14 peptides from Category 2 to Category 1. That means FDA recognized. Potentially prescribable through FDA Set to Review Peptide Access for Compounding Pharmacies Drug Topics HIMS $LLY $NVO The FDA will discuss 7 peptides for possible inclusion on the 503A Bulks List on July 23 24: BPC 157 KPV TB 500 MOTs C Emideltide Semax